( NASDAQ-NMS:OREX )

News from orexigen therapeutics, inc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Jun 22, 2016, 16:30 ET Orexigen Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

 Orexigen Therapeutics, Inc. (NASDAQ: OREX) announced today that the Compensation Committee of the Company's Board of Directors has approved...


Jun 08, 2016, 16:10 ET Orexigen Therapeutics Announces Promotions of Tom Cannell to COO and Jason Keyes to CFO

Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced the promotions of Thomas Cannell, D.V.M., to Executive Vice President, Chief Operating...


Jun 08, 2016, 09:00 ET Orexigen Therapeutics Reports Favorable Markman Ruling in Contrave® Patent Litigation

Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that the United States District Court for the District of Delaware has issued a claim...


May 27, 2016, 16:10 ET Orexigen Announces Upcoming Presentations at European Obesity Summit 2016

Orexigen Therapeutics (NASDAQ: OREX) announced today six poster presentations, including two selected as poster pitch sessions, on naltrexone HCl /...


May 27, 2016, 09:00 ET Orexigen Therapeutics Founder and Former Chairman Eckard Weber Steps Down from Board

 Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that Orexigen co-founder and former Chairman, Eckard Weber, M.D., has resigned from...


May 26, 2016, 09:00 ET Orexigen Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

 Orexigen Therapeutics (NASDAQ: OREX) announced today that the Compensation Committee of the Company's Board of Directors has approved the...


May 23, 2016, 08:30 ET Orexigen Appoints New Member of Board of Directors and Announces Senior Management Changes

Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced the appointment of Deborah A. Jorn to its Board of Directors, effective...


May 04, 2016, 16:01 ET Orexigen Therapeutics Reports Business and Financial Results for the First Quarter Ended March 31, 2016

 Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced business and financial results for the first quarter ended March 31, 2016. "In...


May 03, 2016, 17:30 ET Orexigen Therapeutics to Speak at the Bank of America Merrill Lynch 2016 Health Care Conference

Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the Bank of America Merrill Lynch...


May 03, 2016, 08:30 ET Orexigen Expands Commercial Leadership Team with Appointment of Healthcare Industry Veteran Brian Longstreet as Senior Vice President of Global Market Access and Development

 Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced the appointment of Brian Longstreet as Senior Vice President of Global Market...


May 02, 2016, 08:30 ET Orexigen Announces South Korean Approval of Contrave® (naltrexone HCI and bupropion HCI Extended-Release) Monotherapy for Weight Management in Overweight or Obese Adult Patients

 Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that the Korean Ministry of Food and Drug Safety (MFDS) has approved Contrave®...


Apr 28, 2016, 09:00 ET Orexigen Announces Upcoming Presentations at XIII International Congress on Obesity hosted by the World Obesity Federation

Orexigen Therapeutics (NASDAQ: OREX) announced today upcoming oral and poster presentations on naltrexone HCl / bupropion HCl, marketed as...


Apr 25, 2016, 09:00 ET Orexigen Therapeutics Expands Commercial Capabilities with Appointment of Beth Eastland, Vice President of Sales, and Eight Additional New Employees

 Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced the appointment of Beth Eastland as Vice President of Sales and eight other...


Apr 20, 2016, 17:00 ET Orexigen Therapeutics to Provide Business Update and Discuss First Quarter 2016 Financial Results on May 4, 2016

Orexigen Therapeutics, Inc. (Nasdaq: OREX) will announce corporate and financial results for the first quarter 2016 on Wednesday, May 4th after the...


Mar 15, 2016, 07:05 ET Orexigen Therapeutics to Host Conference Call at 8:30 a.m. Eastern Time Today to Discuss Acquisition of U.S. Rights to Contrave® (naltrexone HCl / bupropion HCl extended release) and Central and Eastern Europe Distribution Agreement with Valeant

 Orexigen Therapeutics, Inc. (Nasdaq: OREX) will host a conference call this afternoon to discuss the strategic acquisition of all U.S. rights...


Mar 15, 2016, 07:00 ET Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Valeant Pharmaceuticals for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) for 18 Central and Eastern European Countries and Turkey

 Orexigen Therapeutics, Inc. (NASDAQ:OREX) today announced Valeant Pharmaceuticals International, Inc. will commercialize Mysimba®...


Mar 15, 2016, 07:00 ET Orexigen announces strategic acquisition of all U.S. rights to Contrave®, the market leading branded anti-obesity prescription medicine

 Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced it has entered into an agreement with Takeda Pharmaceutical Company Limited to...


Mar 15, 2016, 07:00 ET Orexigen and Takeda Jointly Announce Orexigen's Acquisition of All Rights to CONTRAVE® in the United States

 Orexigen Therapeutics, Inc. (Nasdaq: OREX) and Takeda Pharmaceuticals U.S.A., Inc., a wholly-owned subsidiary of Takeda Pharmaceutical...


Feb 26, 2016, 07:00 ET Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2015

Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced business and financial results for the fourth quarter and year ended December 31, 2015....


Feb 19, 2016, 08:30 ET Orexigen Therapeutics to Provide Business Update and Discuss Fourth Quarter and Full Year 2015 Financial Results on February 26, 2016

Orexigen Therapeutics, Inc. (Nasdaq: OREX) will announce corporate and financial results for the fourth quarter and full year 2015 on Friday,...


Feb 18, 2016, 17:00 ET Orexigen Therapeutics to Speak at the RBC Capital Markets 2016 Healthcare Conference

Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that management will participate in a fireside chat discussion at the RBC Capital...


Feb 02, 2016, 16:15 ET Orexigen Therapeutics to Speak at Upcoming Investor Conferences

Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will be presenting at two upcoming investor conferences. The...


Jan 11, 2016, 08:30 ET Orexigen announces 2016 financial outlook and key priorities

 Orexigen Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced key priorities...


Jan 08, 2016, 16:15 ET Orexigen Therapeutics names Thomas Lynch as EVP, General Counsel & Secretary and Heather Ace as EVP, Global Human Resources

 Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced the appointment of Thomas Lynch as Executive Vice President, General Counsel &...


Jan 05, 2016, 16:01 ET Orexigen Therapeutics to Speak at the J.P. Morgan 2016 Global Healthcare Conference

Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the J.P. Morgan 2016 Global...